How should postprandial glycemia be treated?

Diabetes and Metabolism

Volumn 32, Issue HS2, 2006, Pages

  Charpentier, Guillaume ^a   Dardari, D ^a   Riveline, J P ^a  

^a CENTRE HOSPITALIER SUD FRANCILIEN   (France)

Author keywords

Alpha glucosidase inhibitors; Insulin; Metformin; Postprandial glycemia; Sulfonylureas; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT;

ARTICLE; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIFE EXPECTANCY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; BLOOD; DIET RESTRICTION; DRUG ANTAGONISM; HYPERGLYCEMIA; METABOLISM; POSTPRANDIAL STATE; REVIEW;

ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; POSTPRANDIAL PERIOD;

EID: 34248328349     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1262-3636(06)70481-5     Document Type: Article

References (43)

1. 1c. Diabetes Care 2003;26:881-5.
2. Charpentier G, Riveline JP, Dardari D, Varroud-Vial M. Should postprandial hyperglycaemia in prediabetic and type 2 diabetic patients be treated? Drugs 2006;66:273-86.
3. Van Gaal LF, De Leeuw IH.Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003;46 (Suppl. 1):M44-50.
4. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 2003;19:635-41.
5. Sambol NC, Chiang J, O'Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996;36:1012-21.
6. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997;103:483-90.
7. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract 2003;60:161-9.
8. Mudaliar S, Henry R. Thiazolidinediones as PPAR agonists. International textbook of diabetes mellitus, De Fronzo R, Ferrannini E, Keen H, Zimmet P, eds. 2004, pp. 871-900.
9. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72.
10. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet Study Group.Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76. Erratum in: J Clin Endocrinol Metab 2005;90:746.
11. Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ, Tan MH. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005;28:266-72. Erratum in: Diabetes Care 2005;28:1272.
12. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9.
13. Lebovitz HE, Melander A. Sulfonylureas: basic aspect and clinical uses. International textbook of diabetes mellitus, De Fronzo R, Ferrannini E, Keen H, Zimmet P, eds. 2004, pp. 801-32.
14. Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998;38:636-41.
15. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001;18:828-34.
16. Howorka K, Stohr H, Thoma H, Waldhausl W. Multicomponent system for normoglycemic insulin substitution in type 1 diabetic outpatients. Life Support Syst 1985;3(Suppl. 1):540-5.
17. Howorka K, Thoma H, Grillmayr H, Kitzler E. Phases of functional, near-normoglycaemic insulin substitution: what are computers good for in the rehabilitation process in type I (insulin-dependent) diabetes mellitus? Comput Methods Programs Biomed 1990;32:319-23.
18. Anderson EJ, Richardson M, Castle G, et al. Nutrition interventions for intensive therapy in the Diabetes Control and Complications Trial. The DCCT Research Group. J Am Diet Assoc 1993;93:768-72.
19. Winiger G, Keller U, Laager R, Girard J, Berger W. Protein content of the evening meal and nocturnal plasma glucose regulation in type I diabetic subjects. Horm Res 1995;44:101-4.
20. Lebovitz HE. Alpha-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998;6:132-44.
21. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996;19:1190-3.
22. Meneilly GS, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000;23:1162-7.
23. Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002;28:195-200.
24. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 1998;15:485-91.
25. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses.Acta Diabetol 1998;35:34-40.
26. van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154-63.
27. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073-8.
28. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-7.
29. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group.Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-94.
30. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-6.
31. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214-9.
32. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22.
33. Nappo F, Esposito K, Cioffi M, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002;39:1145-50.
34. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767-72.
35. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002;75:492-8.
36. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997;20:1539-42.
37. Poulsen MK, Henriksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003;26:3273-9.
38. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80.
39. Fineman MS, Bicsak TA, Shen LZ, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003;26:2370-7.
40. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69.
41. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-7.
42. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 2006;295:1707-8.
43. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51.